Valuation: Intrexon Corp

Market Cap 2.58B 2.3B 2.14B 1.94B 3.66B 244B 3.72B 25.67B 10.04B 127B 9.67B 9.46B 407B P/E 2026 *
32.3x
P/E 2027 * 11.3x
Enterprise Value 2.58B 2.3B 2.14B 1.94B 3.66B 244B 3.72B 25.67B 10.04B 127B 9.67B 9.46B 407B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 5.81x
Free-Float
87.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2021-09-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 2008-01-31
Director/Board Member 78 2008-01-31
Director/Board Member 70 2011-11-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.21%-3.47% - - 2.63B
Average +1.21%
Weighted average by Cap. +1.21%

Financials

2026 *2027 *
Net sales 239M 213M 198M 180M 339M 22.62B 345M 2.38B 931M 11.8B 896M 877M 37.76B 444M 396M 368M 335M 630M 42.01B 641M 4.42B 1.73B 21.92B 1.66B 1.63B 70.14B
Net income 86.06M 76.82M 71.4M 64.94M 122M 8.15B 124M 858M 336M 4.25B 323M 316M 13.61B 246M 219M 204M 185M 349M 23.25B 355M 2.45B 957M 12.13B 921M 902M 38.82B
Net Debt - -
Logo Intrexon Corp
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Intrexon Corp